<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01781104</url>
  </required_header>
  <id_info>
    <org_study_id>RM-131-006</org_study_id>
    <nct_id>NCT01781104</nct_id>
  </id_info>
  <brief_title>Phase 2 Study to Evaluate Safety and Efficacy of RM-131 Administered to Patients With Chronic Constipation</brief_title>
  <official_title>A Phase 2, Randomized, Double-blind, Placebo-controlled, Multiple Dose, Parallel Group Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of RM-131 Administered to Patients With Chronic Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Motus Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Motus Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate safety and tolerability as well as the effects of&#xD;
      RM-131 on colonic transit, bowel consistency, bowel habits, abdominal pain, and other&#xD;
      abdominal symptoms in patients with chronic constipation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of RM-131 on colonic transit</measure>
    <time_frame>End of 14 day Baseline and end of 14 day Treatment periods</time_frame>
    <description>Change from baseline colonic geometric center at 24 hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability of RM-131</measure>
    <time_frame>Duration of the study, an expected average of 9 weeks</time_frame>
    <description>Assessment of adverse events and clinical laboratory evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of RM-131 on stool consistency</measure>
    <time_frame>Daily for the duration of the study, an expected average of 9 weeks</time_frame>
    <description>Change in responses on Bowel Habit Diary Cards</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Constipation</condition>
  <arm_group>
    <arm_group_label>RM-131</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>RM-131</intervention_name>
    <description>Double blind RM-131 (100 ug) will be delivered subcutaneously once daily for 14 days.</description>
    <arm_group_label>RM-131</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo delivered subcutaneously once daily for 14 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Able to provide written informed consent prior to any study procedures, and willing&#xD;
             and able to comply with study procedures.&#xD;
&#xD;
          -  Diagnosis of chronic IDIOPATHIC constipation, including experiencing constipation for&#xD;
             12 or more weeks in the preceding 12 months (defined by Rome III criteria for&#xD;
             Functional Constipation, but all patients must meet the modified criterion of a&#xD;
             history of â‰¤4 average defecations per week)&#xD;
&#xD;
          -  Stable concomitant medications (no changes in regimen for at least 2 weeks prior to&#xD;
             baseline period)&#xD;
&#xD;
          -  Body mass index of 18-40 kg/m2&#xD;
&#xD;
          -  Females must not be lactating or pregnant&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Unable/unwilling to provide informed consent or to comply with study procedures&#xD;
&#xD;
          -  Diagnosis of secondary constipation e.g. underlying general neurological disease such&#xD;
             as Parkinsonism, multiple sclerosis, diseases associated with peripheral neuropathy,&#xD;
             iatrogenic constipation&#xD;
&#xD;
          -  Structural or metabolic diseases that affect the GI system NOTE: Patients with&#xD;
             clinical suspicion of upper or lower GI obstruction must have been evaluated per&#xD;
             standard of care and obstruction ruled out before screening&#xD;
&#xD;
          -  Unable to withdraw the following medications 48 hours prior to baseline period and&#xD;
             throughout the study (except as protocol defined rescue medications):&#xD;
&#xD;
               -  Medications that alter GI transit including laxatives, magnesium and aluminum&#xD;
                  containing antacids, prokinetics, erythromycin, narcotics, anti-cholinergics,&#xD;
                  tricyclic antidepressants, SNRI and newer antidepressants&#xD;
&#xD;
               -  Selective serotonin reuptake inhibitor (SSRI) antidepressants are permissible at&#xD;
                  low, stable doses&#xD;
&#xD;
               -  Analgesic drugs including opiates, NSAIDs and COX-2 inhibitors&#xD;
&#xD;
               -  GABAnergic agents&#xD;
&#xD;
               -  Benzodiazepines&#xD;
&#xD;
          -  NOTE: stable doses of thyroid replacement, estrogen replacement, low dose aspirin for&#xD;
             cardioprotection, and birth control (but with adequate backup contraception as&#xD;
             drug-interactions with birth control have not been conducted) are permissible&#xD;
&#xD;
          -  Drugs with a low therapeutic index, such as warfarin, digoxin, anti-seizure&#xD;
             medications&#xD;
&#xD;
          -  History of surgery within 60 days of screening&#xD;
&#xD;
          -  Acute or chronic illness or history of illness, which in the opinion of Investigator,&#xD;
             could pose threat/harm to the patient or obscure interpretation of laboratory test&#xD;
             results or interpretation of study data such as frequent angina, Class III or IV&#xD;
             congestive heart failure, moderate impairment of renal or hepatic function, poorly&#xD;
             controlled diabetes, etc&#xD;
&#xD;
          -  History of hypersensitivity to mannitol (an ingredient of both active and placebo&#xD;
             study medications)&#xD;
&#xD;
          -  Clinically significant abnormalities on screening laboratories or physical examination&#xD;
             as determined by Investigator&#xD;
&#xD;
          -  Abnormal 12-lead electrocardiogram (ECG), including evidence of acute myocardial or&#xD;
             subendocardial ischemia and clinically significant arrhythmias or conduction&#xD;
             abnormalities (including prolonged QTc &gt; 500 msec) or abnormal blood pressure at&#xD;
             screening except minor deviations deemed to be of no clinical significance by&#xD;
             Investigator&#xD;
&#xD;
          -  Acute GI illness within 48 hours of initiation of the baseline period&#xD;
&#xD;
          -  ALT or AST &gt; 1.2 X upper limit of normal during screening&#xD;
&#xD;
          -  Females who are pregnant or breastfeeding&#xD;
&#xD;
          -  History of excessive alcohol use or substance abuse&#xD;
&#xD;
          -  Participation in an investigational clinical study within 30 days prior to dosing in&#xD;
             the present study&#xD;
&#xD;
          -  Any other reason, which in the opinion of the Investigator, would confound proper&#xD;
             interpretation of the study&#xD;
&#xD;
        Exclusion criteria at the end of the baseline period&#xD;
&#xD;
          -  In addition, patients will not be randomized into the double-blind treatment&#xD;
             comparison if during the baseline period they:&#xD;
&#xD;
          -  used rescue medications such as laxatives, beyond those allowed by protocol&#xD;
&#xD;
          -  demonstrated lack of compliance&#xD;
&#xD;
          -  averaged more than 4 spontaneous bowel movements per week&#xD;
&#xD;
          -  Substudy patients only: did not demonstrate slow colonic transit at end of baseline&#xD;
             period (GC 24 &gt;2.4)&#xD;
&#xD;
          -  Women of child-bearing potential: positive pregnancy test&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Elizabeth Stoner, MD</last_name>
    <role>Study Director</role>
    <affiliation>Rhythm Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <study_first_submitted>January 28, 2013</study_first_submitted>
  <study_first_submitted_qc>January 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2013</study_first_posted>
  <disposition_first_submitted>November 6, 2014</disposition_first_submitted>
  <disposition_first_submitted_qc>November 6, 2014</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 19, 2014</disposition_first_posted>
  <last_update_submitted>September 21, 2016</last_update_submitted>
  <last_update_submitted_qc>September 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 23, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>constipation gastric emptying gastrointestinal motility ghrelin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

